Breakthrough in Base Editing Therapy Achieves Lasting Remission for Sickle Cell Disease and Beta-Thalassemia

Pioneering Advances in Gene Therapy for Hemoglobin Disorders

On September 7, 2026, a remarkable advancement in the treatment of blood disorders was unveiled at the Shanghai-based journal Cell Stem Cell. This study, spearheaded by CorrectSequence Therapeutics (Correctseq), offered groundbreaking evidence on the effectiveness of their tBE-mediated base editing therapy for sickle cell disease (SCD) and beta-thalassemia (β-thalassemia) across various genetic backgrounds.

Clinical Study Insights

The study's findings were based on a clinical trial involving several international patients, reinforcing that the tBE approach effectively fosters clinical remission regardless of the participants' genetic profiles. This promising research showcases the success achieved with CS-101/CS-206, therapies developed utilizing the transformer Base Editor (tBE). Previously, the Correctseq team published findings revealing total transfusion independence in five Chinese patients suffering from transfusion-dependent β-thalassemia (TDT). This recent study built on that groundbreaking work by extending the treatment to patients from diverse ethnical backgrounds, including Nigeria, Laos, Malaysia, and Pakistan.

The results revealed that the patients enjoying healthcare benefits from this therapy exhibited a rapid reconstitution of hematopoiesis, sustained high levels of HbF, total transfusion independence, and a notable reduction in vaso-occlusive crises (VOC), all without any detectable off-target modifications or product-related adverse events.

Wide Applicability Across Ethnicities

These beta-hemoglobinopathies are prevalent worldwide, affecting over 300,000 newborns annually for sickle cell disease and more than 40,000 for transfusion-dependent β-thalassemia. The genetic mutations varied significantly across different populations. The proficient application of the tBE method was previously verified in healthy individuals before now being confirmed for various patient backgrounds. The ongoing enhancement of this precise editing technique not only sweetens the possibilities for treating such conditions but potentially opens new avenues in gene therapy.

Clinical Performance Metrics

The SCD patient involved in the study, a 21-year-old woman from Nigeria, achieved a neutrophil and platelet engraftment on the 13th and 21st days after infusion, respectively. Her total hemoglobin level elevated from 7.7 g/dL to 12.9 g/dL within three months and maintained above 11 g/dL. Notably, her HbF levels increased from 3.5% to a remarkable 62.2%. After a follow-up period of 15.5 months, she had shown no VOC incidents.

Furthermore, the study found that three patients suffering from TDT aged between 3 and 29 years, also exhibited rapid engraftment rates, solidifying the treatment's reliability across various demographics.

Comparatively Enhanced Engraftment Rates

When examined against traditional gene editing therapies like Cas9 and Cas12a, the tBE showed notably faster engraftment of neutrophils and platelets. Not only did it showcase an improved safety profile with no significant off-target mutations, but it also maintained elevated HbF levels significantly above 60%, far exceeding the capabilities of earlier therapies.

The innovative tBE avoids the common pitfalls of DNA double-strand breaks, making it a favorable choice in further research for genetic treatments.

Global Progress and Future Endeavors

As of now, more than 30 patients have received the CS-101 and CS-206 treatments globally, all achieving either transfusion independence or experienced no occurrence of VOC. The rapid advancement of these treatments underscores the potential for widespread application beyond blood disorders to tackle metabolic and cardiovascular diseases such as familial hypertriglyceridemia and hypercholesterolemia.

Professor Chen Jia, founder of Correctseq and director of the Gene Editing Center at ShanghaiTech University, hailed the findings as a testament to the expansive applicability of tBE on diverse genetic configurations. Moreover, they continue to explore RNA editing, prime editing, and mitochondrial DNA modification in therapeutic contexts.

Dr. Mou Xiaodun, CEO of Correctseq, emphasized their efforts in expanding therapeutic options for metabolic diseases, aiming for early market authorization to benefit more patients globally.

In conclusion, this clinical study not only reinforces the role of advanced gene editing technologies in modern medicine but also highlights the continuous strides being made toward personalized therapeutic interventions with the potential to alter the treatment landscape for various genetic disorders.